Ruhi Ahmed

Ruhi Ahmed, Ph.D., serves as Head of Regulatory affairs. She has nearly 20 years of experience in the pharmaceutical and biotechnology industries doing global regulatory drug development as well as program and portfolio management of assets from the preclinical to the commercial stage.

Prior to joining Asceneuron, Dr. Ahmed held positions at Inozyme Pharmaceutical Inc., UltraGenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc. and Actavis Inc. (formerly Watson Pharmaceutical Inc.). Her expertise encompasses leading the preclinical, clinical and manufacturing regulatory strategy and submissions for multiple INDs and marketing applications for a variety of neuromuscular, respiratory, cardiovascular, oncology and metabolic rare disease indications. She also led the alliance management and program strategy for several investigational prodrugs, biologics and small molecules.

Dr. Ahmed earned her B.S. in Biology and M.A. in Biochemistry from The University of Texas at Austin and her M.S. in Regulatory Sciences and Ph.D. in molecular pharmacology and toxicology from the University of Southern California.